CD47 blockade augments anti-GD2 driven phagocytosis in vitro but fails to improve in vivo efficacy in immunocompetent, chemoresistant neuroblastoma preclinical models
4 affiliations
- 1University College London, Institute of Child Health, London, United Kingdom
- 2Institute of Cancer Research, Sutton, United Kingdom
- 3University of Wisconsin, Wisconsin, United States of America
- 4Dana Farber Cancer Institute, Boston, United States of America
Abstract
CD47 delivers a dominant “Don’t Eat Me” signal that inhibits macrophage‑mediated clearance of tumour cells. Using immunocompetent, chemoresistant neuroblastoma (NB) models, we tested a Fc‑silent CD47 blocker (ALX301) with anti‑GD2 antibody alone and in combination with a clinically aligned temozolomide/irinotecan chemoimmunotherapy backbone. Tumours expressed GD2 and CD47, and bound ALX301. In macrophage coculture assays, anti-GD2 antibody induced dose-dependent phagocytosis, whereas ALX301 or an anti-CD47 antibody alone did not. CD47 blockade in combination with a suboptimal concentration of anti-GD2 antibody showed an additive effect on phagocytosis in vitro. In vivo, however, ALX301 failed to improve tumour control or survival when added to anti‑GD2 or to chemoimmunotherapy in the dosing regimens and two independent models tested. Toxicity was acceptable, showing only mild, expected red‑cell changes without overt organ injury. This form of CD47 inhibition is therefore mechanistically active in vitro but insufficient to enhance anti‑GD2 antibody-based therapy in immunocompetent mice bearing a chemoresistant NB, highlighting the potential need for myeloid‑reprogramming partners.
Related
- 830 mLIGHT-armed oncolytic myxoma virus combined with selinexor and PD-1 blockade reduces pulmonary metastatic burden in an immunocompetent murine melanoma model
- Quantifying the energetic costs and growth benefits of phagocytosis
- Vpu protects HIV-infected cells from antibody-dependent cellular phagocytosis by counteracting tetherin
- Exploring glycocalyx components powering the contact between Entamoeba histolytica and bacteria during non-opsonic phagocytosis
- Macrophages use sub-micron actin ridges in phagocytosis of encapsulated fungal pathogens
BibTeX
@article{himsworth2026cd47,
title = {{CD47 blockade augments anti-GD2 driven phagocytosis in vitro but fails to improve in vivo efficacy in immunocompetent, chemoresistant neuroblastoma preclinical models}},
author = {Courtney Himsworth and Thomas Jackson and Chantelle Bowers and Sophie Munnings-Tomes and Gaya Nair and Henrike Muller and Elizabeth Tucker and Amy K. Erbe-Gurel and Paul M. Sondel and Louis Chesler and Robbie Mazjner and John Anderson},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0353900},
url = {https://doi.org/10.1371/journal.pone.0353900},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - CD47 blockade augments anti-GD2 driven phagocytosis in vitro but fails to improve in vivo efficacy in immunocompetent, chemoresistant neuroblastoma preclinical models
AU - Courtney Himsworth
AU - Thomas Jackson
AU - Chantelle Bowers
AU - Sophie Munnings-Tomes
AU - Gaya Nair
AU - Henrike Muller
AU - Elizabeth Tucker
AU - Amy K. Erbe-Gurel
AU - Paul M. Sondel
AU - Louis Chesler
AU - Robbie Mazjner
AU - John Anderson
PY - 2026
DA - 2026/10/27
JO - PLOS One
DO - 10.1371/journal.pone.0353900
UR - https://doi.org/10.1371/journal.pone.0353900
AB - CD47 delivers a dominant “Don’t Eat Me” signal that inhibits macrophage‑mediated clearance of tumour cells. Using immunocompetent, chemoresistant neuroblastoma (NB) models, we tested a Fc‑silent CD47 blocker (ALX301) with anti‑GD2 antibody alone and in combination with a clinically aligned temozolomide/irinotecan chemoimmunotherapy backbone. Tumours expressed GD2 and CD47, and bound ALX301. In macrophage coculture assays, anti-GD2 antibody induced dose-dependent phagocytosis, whereas ALX301 or an anti-CD47 antibody alone did not. CD47 blockade in combination with a suboptimal concentration of anti-GD2 antibody showed an additive effect on phagocytosis in vitro. In vivo, however, ALX301 failed to improve tumour control or survival when added to anti‑GD2 or to chemoimmunotherapy in the dosing regimens and two independent models tested. Toxicity was acceptable, showing only mild, expected red‑cell changes without overt organ injury. This form of CD47 inhibition is therefore mechanistically active in vitro but insufficient to enhance anti‑GD2 antibody-based therapy in immunocompetent mice bearing a chemoresistant NB, highlighting the potential need for myeloid‑reprogramming partners.
SN - 1932-6203
ER -